Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma

Richard P. Kadota, Donald H. Mahoney, John Doyle, Reggie Duerst, Henry Friedman, Emi Holmes, Larry Kun, Tianni Zhou, Ian F. Pollack

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Purpose. To determine the response, toxicity, and survival for children with progressive or recurrent medulloblastoma and germinoma using a single myeloablative course of chemotherapy supported by autologous hematopoietic stem cells. Patients and Methods. Subjects were in second remission or had minimal residual disease at the time of study entry. The conditioning regimen consisted of cyclophosphamide 6,000 mg/m2 plus melphalan 180 mg/m2. Results. Twenty-nine evaluable pediatric patients were accrued. The most frequent major toxicities were myelosuppression, infections, and stomatitis, but no toxic deaths were recorded. Best responses were: CR = 6, CCR = 13, PR = 6, SD = 2, and PD = 2. There were 6 medulloblastoma and 3 germinoma survivors with a median follow-up of 7.5 years (range = 2.8-10). Two germinoma survivors received radiotherapy after autografting for presumptive progressive disease. Conclusion. Myeloablative chemotherapy consisting of cyclophosphamide and melphalan was tolerable in the relapsed brain tumor setting with 19/29 cases achieving CR or CCR status and 9/29 becoming long-term survivors.

Original languageEnglish (US)
Pages (from-to)675-678
Number of pages4
JournalPediatric Blood and Cancer
Volume51
Issue number5
DOIs
StatePublished - Nov 1 2008

Fingerprint

Germinoma
Medulloblastoma
Melphalan
Hematopoietic Stem Cells
Cyclophosphamide
Survivors
Drug Therapy
Stomatitis
Time and Motion Studies
Autologous Transplantation
Poisons
Residual Neoplasm
Brain Neoplasms
Radiotherapy
Pediatrics
Survival
Infection

Keywords

  • Autograft
  • Chemotherapy
  • Germinoma
  • Medulloblastoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Kadota, R. P., Mahoney, D. H., Doyle, J., Duerst, R., Friedman, H., Holmes, E., ... Pollack, I. F. (2008). Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma. Pediatric Blood and Cancer, 51(5), 675-678. https://doi.org/10.1002/pbc.21655

Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma. / Kadota, Richard P.; Mahoney, Donald H.; Doyle, John; Duerst, Reggie; Friedman, Henry; Holmes, Emi; Kun, Larry; Zhou, Tianni; Pollack, Ian F.

In: Pediatric Blood and Cancer, Vol. 51, No. 5, 01.11.2008, p. 675-678.

Research output: Contribution to journalArticle

Kadota, RP, Mahoney, DH, Doyle, J, Duerst, R, Friedman, H, Holmes, E, Kun, L, Zhou, T & Pollack, IF 2008, 'Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma', Pediatric Blood and Cancer, vol. 51, no. 5, pp. 675-678. https://doi.org/10.1002/pbc.21655
Kadota, Richard P. ; Mahoney, Donald H. ; Doyle, John ; Duerst, Reggie ; Friedman, Henry ; Holmes, Emi ; Kun, Larry ; Zhou, Tianni ; Pollack, Ian F. / Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma. In: Pediatric Blood and Cancer. 2008 ; Vol. 51, No. 5. pp. 675-678.
@article{10d977b721fb47e29cc71579917847fd,
title = "Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma",
abstract = "Purpose. To determine the response, toxicity, and survival for children with progressive or recurrent medulloblastoma and germinoma using a single myeloablative course of chemotherapy supported by autologous hematopoietic stem cells. Patients and Methods. Subjects were in second remission or had minimal residual disease at the time of study entry. The conditioning regimen consisted of cyclophosphamide 6,000 mg/m2 plus melphalan 180 mg/m2. Results. Twenty-nine evaluable pediatric patients were accrued. The most frequent major toxicities were myelosuppression, infections, and stomatitis, but no toxic deaths were recorded. Best responses were: CR = 6, CCR = 13, PR = 6, SD = 2, and PD = 2. There were 6 medulloblastoma and 3 germinoma survivors with a median follow-up of 7.5 years (range = 2.8-10). Two germinoma survivors received radiotherapy after autografting for presumptive progressive disease. Conclusion. Myeloablative chemotherapy consisting of cyclophosphamide and melphalan was tolerable in the relapsed brain tumor setting with 19/29 cases achieving CR or CCR status and 9/29 becoming long-term survivors.",
keywords = "Autograft, Chemotherapy, Germinoma, Medulloblastoma",
author = "Kadota, {Richard P.} and Mahoney, {Donald H.} and John Doyle and Reggie Duerst and Henry Friedman and Emi Holmes and Larry Kun and Tianni Zhou and Pollack, {Ian F.}",
year = "2008",
month = "11",
day = "1",
doi = "10.1002/pbc.21655",
language = "English (US)",
volume = "51",
pages = "675--678",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma

AU - Kadota, Richard P.

AU - Mahoney, Donald H.

AU - Doyle, John

AU - Duerst, Reggie

AU - Friedman, Henry

AU - Holmes, Emi

AU - Kun, Larry

AU - Zhou, Tianni

AU - Pollack, Ian F.

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Purpose. To determine the response, toxicity, and survival for children with progressive or recurrent medulloblastoma and germinoma using a single myeloablative course of chemotherapy supported by autologous hematopoietic stem cells. Patients and Methods. Subjects were in second remission or had minimal residual disease at the time of study entry. The conditioning regimen consisted of cyclophosphamide 6,000 mg/m2 plus melphalan 180 mg/m2. Results. Twenty-nine evaluable pediatric patients were accrued. The most frequent major toxicities were myelosuppression, infections, and stomatitis, but no toxic deaths were recorded. Best responses were: CR = 6, CCR = 13, PR = 6, SD = 2, and PD = 2. There were 6 medulloblastoma and 3 germinoma survivors with a median follow-up of 7.5 years (range = 2.8-10). Two germinoma survivors received radiotherapy after autografting for presumptive progressive disease. Conclusion. Myeloablative chemotherapy consisting of cyclophosphamide and melphalan was tolerable in the relapsed brain tumor setting with 19/29 cases achieving CR or CCR status and 9/29 becoming long-term survivors.

AB - Purpose. To determine the response, toxicity, and survival for children with progressive or recurrent medulloblastoma and germinoma using a single myeloablative course of chemotherapy supported by autologous hematopoietic stem cells. Patients and Methods. Subjects were in second remission or had minimal residual disease at the time of study entry. The conditioning regimen consisted of cyclophosphamide 6,000 mg/m2 plus melphalan 180 mg/m2. Results. Twenty-nine evaluable pediatric patients were accrued. The most frequent major toxicities were myelosuppression, infections, and stomatitis, but no toxic deaths were recorded. Best responses were: CR = 6, CCR = 13, PR = 6, SD = 2, and PD = 2. There were 6 medulloblastoma and 3 germinoma survivors with a median follow-up of 7.5 years (range = 2.8-10). Two germinoma survivors received radiotherapy after autografting for presumptive progressive disease. Conclusion. Myeloablative chemotherapy consisting of cyclophosphamide and melphalan was tolerable in the relapsed brain tumor setting with 19/29 cases achieving CR or CCR status and 9/29 becoming long-term survivors.

KW - Autograft

KW - Chemotherapy

KW - Germinoma

KW - Medulloblastoma

UR - http://www.scopus.com/inward/record.url?scp=52249110902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52249110902&partnerID=8YFLogxK

U2 - 10.1002/pbc.21655

DO - 10.1002/pbc.21655

M3 - Article

C2 - 18623206

AN - SCOPUS:52249110902

VL - 51

SP - 675

EP - 678

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 5

ER -